Literature DB >> 19635733

Pulmonary resection for metastases from colorectal carcinoma.

Ryo Maeda1, Noritaka Isowa, Hideyuki Onuma, Hiroshi Miura, Tomoya Harada, Hirokazu Touge, Hirokazu Tokuyasu, Yuji Kawasaki.   

Abstract

A pulmonary resection of metastatic colorectal carcinoma is an accepted method of treatment. The purpose of this study was to confirm the role of resections for pulmonary metastases from colorectal carcinoma, and to determine the clinical course, outcome, and prognostic factors after surgery. A retrospective analysis was conducted of the records of all patients with pulmonary metastases from colorectal carcinoma who underwent a surgical resection between 1995 and 2008, at a single surgical center. The overall 5-year survival rate was 74%. Multivariate Cox analysis demonstrated that the number of pulmonary metastases (HR: 9.40, 95% confidence interval (CI): 1.08-82.2, P=0.0428) and prethoracotomy carcinoembryonic antigen (CEA) level (HR: 9.79, 95% CI: 1.11-86.8, P=0.0404) were statistically significant predictors of survival after the first pulmonary metastasectomy. In addition, a second resection for recurrent metastases was performed in eight patients, and a third resection was done in one patient. There were no major postoperative complications among the patients who underwent second or third resections. Pulmonary resections are considered to be a safe and effective treatment in selective patients.

Entities:  

Mesh:

Year:  2009        PMID: 19635733     DOI: 10.1510/icvts.2009.202598

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  7 in total

1.  Clinical outcomes of lung metastasectomy in patients with colorectal cancer.

Authors:  Omer Fatih Olmez; Erdem Cubukcu; Ahmet Sami Bayram; Unsal Akcali; Turkkan Evrensel; Cengiz Gebitekin
Journal:  World J Gastroenterol       Date:  2012-02-21       Impact factor: 5.742

2.  Lung metastasectomy after colorectal cancer: prognostic impact of resection margin on long term survival, a retrospective cohort study.

Authors:  Federico Davini; Sara Ricciardi; Carmelina C Zirafa; Gaetano Romano; Greta Alì; Gabriella Fontanini; Franca M A Melfi
Journal:  Int J Colorectal Dis       Date:  2019-11-04       Impact factor: 2.571

Review 3.  Management of resectable colorectal lung metastases.

Authors:  Sing Yu Moorcraft; George Ladas; Anne Bowcock; Ian Chau
Journal:  Clin Exp Metastasis       Date:  2015-12-10       Impact factor: 5.150

4.  Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer.

Authors:  Nedim Turan; Mustafa Benekli; Faysal Dane; Olcun Umit Unal; Hasan Volkan Kara; Dogan Koca; Ozlem Balvan; Tulay Eren; Didem Tastekin; Kaan Helvaci; Veli Berk; Umut Demirci; Selcuk Cemil Ozturk; Erkan Dogan; Bulent Cetin; Mehmet Kucukoner; Onder Tonyali; Gulnihal Tufan; Ilhan Oztop; Mahmut Gumus; Ugur Coskun; Aytug Uner; Ahmet Ozet; Suleyman Buyukberber
Journal:  Thorac Cancer       Date:  2014-08-25       Impact factor: 3.500

5.  The clinical value of circulating tumour cells (CTCs) in patients undergoing pulmonary metastasectomy for metastatic colorectal cancer.

Authors:  Masaki Hashimoto; Fumihiro Tanaka; Kazue Yoneda; Teruhisa Takuwa; Ayumi Kuroda; Seiji Matsumoto; Yoshitomo Okumura; Nobuyuki Kondo; Tohru Tsujimura; Takashi Nakano; Seiki Hasegawa
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

6.  SNORA21 - An Oncogenic Small Nucleolar RNA, with a Prognostic Biomarker Potential in Human Colorectal Cancer.

Authors:  Kazuhiro Yoshida; Shusuke Toden; Wenhao Weng; Kunitoshi Shigeyasu; Jinsei Miyoshi; Jacob Turner; Takeshi Nagasaka; Yanlei Ma; Tetsuji Takayama; Toshiyoshi Fujiwara; Ajay Goel
Journal:  EBioMedicine       Date:  2017-07-12       Impact factor: 8.143

7.  Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases.

Authors:  Eliza A Hawkes; George Ladas; David Cunningham; Andrew G Nicholson; Katharina Wassilew; Yolanda Barbachano; Gihan Ratnayake; Sheela Rao; Ian Chau
Journal:  BMC Cancer       Date:  2012-08-01       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.